Biomea Fusion, Inc.

BMEA Healthcare Biotechnology

In the quarter to June 2026, EPS grew 76.5% and free cash flow grew 47.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.87 0.03 +3.57%
Market cap
$60.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(209.00%) (152.35%) (189.44%) (164.14%)
ROA
(115.59%) (89.23%) (88.62%) (59.14%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(280.88%) (131.20%) (121.19%) (125.18%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(1.44) (1.35) (0.78) (0.65)
Free Cash Flow
(86.43) (70.37) (56.15) (46.91)
Capital Expenditures
— — 0.22 0.28
Other line items
Cash ROIC
(138.82%) (82.44%) (88.04%) (99.11%)
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Operating CF/Net income
0.90 1.14 1.25 1.45
Depreciation/Fixed assets
9.16 9.21 14.73 11.49
Capex/Depreciation
0.00 0.00 0.23 0.52
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(1.44) (1.35) (0.78) (0.65)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
— — 0.00 0.00

Fold the line items

Columns are period end dates